Pharmacogenetics in affective disorders

European Journal of Pharmacology
A SerrettiE Smeraldi

Abstract

Pharmacogenetics will be of substantial help in the field of affective disorders pharmacotherapy. The possible definition of a genetic liability profile for drug side-effects and efficacy will be of great help in treatments that need weeks to months to be effective. During the last few years, a number of groups have reported possible liability genes. The efficacy and time of onset of selective serotonin reuptake inhibitors have been associated with a polymorphism in the promoter region of the transporter (SERTPR) in many independent studies, while variants at the tryptophan hydroxylase gene, 5-HT2a receptor and G-protein beta3 have been associated with them in pilot studies. Lithium long-term prophylactic efficacy has been associated with SERTPR, TPH and inositol polyphosphate 1-phosphatase variants, though in unreplicated samples. A number of further candidate genes were not associated with these treatments. In conclusion, both acute and long-term treatments appear to be, at least to some extent, under genetic influence and preliminary data have identified possible liability genes.

References

Jul 9, 1992·Nature·H H Van TolV Jovanovic
Jan 1, 1992·Pharmacology & Toxicology·A MørkP Hollund
Jun 1, 1992·Journal of Affective Disorders·L BelliniE Smeraldi
Jan 1, 1990·Journal of Psychiatric Research·Y OdagakiI Yamashita
May 7, 1990·Biochimica Et Biophysica Acta·L BirnbaumerA M Brown
Jul 25, 1990·Nucleic Acids Research·S BoularandJ Mallet
Jan 1, 1989·Progress in Neuro-psychopharmacology & Biological Psychiatry·G M Goodwin
Mar 1, 1986·The American Journal of Nursing·B Harris
Mar 1, 1986·Journal of Affective Disorders·M T Abou-Saleh, A Coppen
Jan 1, 1987·Annual Review of Biochemistry·A G Gilman
May 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·C R GerfenS G Rhee
Mar 1, 1987·Archives of General Psychiatry·F M QuitkinW Harrison
Dec 1, 1967·The British Journal of Social and Clinical Psychology·M Hamilton
Apr 1, 1984·Journal of Affective Disorders·E SmeraldiK K Kidd
Oct 1, 1984·Journal of Affective Disorders·E SmeraldiA Orsini
Aug 1, 1984·Archives of General Psychiatry·F M QuitkinJ W Stewart
Aug 1, 1982·Archives of General Psychiatry·J F LeckmanM M Weissman
Jul 1, 1995·Archives of General Psychiatry·H K ManjiR H Lenox
Apr 3, 1995·Brain Research·P W BurnetP J Harrison
Oct 1, 1994·Journal of Affective Disorders·P GrofM Walsh
Jan 1, 1994·Journal of Neural Transmission. General Section·K P LeschP Riederer
Dec 1, 1994·Journal of Affective Disorders·L FranchiniE Smeraldi
Nov 15, 1993·Biochemical and Biophysical Research Communications·M ItokawaM Toru
May 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R CavallaroE Smeraldi

❮ Previous
Next ❯

Citations

Mar 16, 2007·Archives of Oral Biology·Paôlla Freitas PerdigãoRicardo Santiago Gomez
Mar 17, 2004·Current Opinion in Pharmacology·Brigitta Bondy, Peter Zill
Jun 11, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Marcelo Páez-Pereda
Sep 5, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Pierre BaumannChin B Eap
Dec 14, 2004·BMC Medical Genetics·Alessandro Serretti, Enrico Smeraldi
Jun 24, 2008·Neuropsychiatric Disease and Treatment·Francis E Lotrich, Bruce G Pollock
Feb 4, 2003·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·Alessandro Serretti, Paola Artioli
May 25, 2010·The Journal of Clinical Psychiatry·Giacomo SalvadoreCarlos A Zarate
Nov 5, 2010·Pharmacogenomics·Michael J McCarthyJohn R Kelsoe
Aug 11, 2005·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Junia Maria Netto VictoriaRicardo Santiago Gomez
Jul 28, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Reiji YoshimuraNobuhisa Ueda
Sep 19, 2006·Studies in History and Philosophy of Biological and Biomedical Sciences·Tom Ling, Ann Raven
Jun 14, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Klaus Peter Lesch, Lise Gutknecht
Oct 24, 2003·Biological Psychiatry·Roy H PerlisMaurizio Fava
Sep 26, 2002·Expert Review of Molecular Diagnostics·Eva Halapi, Hakon Hakonarson
Oct 3, 2006·Pharmacology & Therapeutics·Sharon Rosenzweig-LipsonLee E Schechter
Apr 28, 2004·The Pharmacogenomics Journal·A Serretti, P Artioli
Mar 31, 2004·Molecular Psychiatry·E J PetersS P Hamilton
Mar 7, 2020·Journal of Clinical Psychopharmacology·Lindsay M Melhuish BeaupreJames L Kennedy

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved